The global market for transdermal patches is experiencing rapid transformation, providing advanced solutions for the controlled administration of therapeutic agents across a range of medical ...

Dublin, March 05, 2024 (GLOBE NEWSWIRE) -- The "Global Transdermal Patches Market by Type (Drug-in-adhesives, Matrix, Reservoir Membrane), Adhesive (Acrylic, Silicone ...

As more and more research hints at the potential therapeutic uses of psychedelics, finding new ways to deliver the powerful drugs has taken on new interest. For example, the active component of ...

Nutriband Inc. today announced that it has signed an exclusive distribution agreement with Costa Rica Based Innomedica for AVERSA Fentanyl upon approval and all sports tape products manufactured at ...

Fentanyl transdermal patch is available as a generic drug and as a brand-name drug. Brand name: Duragesic. Fentanyl also comes as a buccal and sublingual tablet, oral lozenge, sublingual spray, nasal ...

Patches that stick to the skin, even during exercise, are now available in a variety of formulas that contain treatment-specific ratios of cannabidiol (CBD) to THC. (Photo courtesy of Papa & Barkley) ...

The US Food and Drug Administration (FDA) has approved donepezil transdermal system (Adlarity) for patients with mild, moderate, or severe Alzheimer's disease (AD), the manufacturer has announced.

An innovative delivery method for human immunodeficiency virus medications has been developed through use of a transdermal patch, the first of its kind to treat HIV. An innovative delivery method for ...

March 30, 2011 (Toronto, Ontario) — Caregivers using a transdermal patch to administer cholinesterase inhibitor (ChEI)–based therapy in individuals with Alzheimer's disease (AD) report greater overall ...

It looks to me that Kimberly Clark (UK) are targeting the $3B transdermal patch market using imprint technology in a new development program with imprint supplier – Obducat (Sweden). Kimberly-Clark is ...

Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks. Eight years ago, I wrote about a startup trying to deliver cancer ...